Terminated PHASE1 INTERVENTIONAL 2-arm NCT05549323

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

A PHASE 1B, TWO-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ORAL PF-07054894 IN ADULT PARTICIPANTS AGED 18-75 YEARS WITH MILD TO SEVERE ULCERATIVE COLITIS

Sponsor: Pfizer

Conditions Ulcerative Colitis

Interventions PF-07054894 Placebo

Updated 27 times since 2022 Last updated: Feb 24, 2026 Started: Nov 7, 2022 Primary completion: Nov 11, 2025 Completion: Nov 11, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to business decision. The decision to terminate the trial was not based on any safety concerns associated with PF-07054894.

Other terminated trials from Pfizer

See all terminations from Pfizer

Other Ulcerative Colitis trials with similar outcome

Browse all Ulcerative Colitis trials

A PHASE1 clinical study on Ulcerative Colitis, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 27 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

27 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE1
Jan 2026 — Feb 2026 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Oct 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1

▶ Show 22 earlier versions

May 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Feb 2025 — May 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Feb 2025 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1
May 2023 — Jul 2023 [monthly]

Recruiting PHASE1
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE1
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bialystok, Poland , Bydgoszcz, Poland , Elblag, Poland , Iowa City, United States , Kissimmee, United States , Knurów, Poland , Krakow, Poland , Lodz, Poland , Piotrkow Trybunalski, Poland and 3 more locations